Teva-Xenon painkiller wins orphan designation from FDA

04/24/2013 | Pharmaceutical Business Review Online

The FDA has granted orphan-drug status to Teva Pharmaceutical and Xenon Pharmaceuticals' XEN402, an experimental drug for pain associated with erythromelalgia. A midstage trial showed that the drug, which inhibits the SCN9A sodium channel, alleviates erythromelalgia-related pain.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC